XBiotech (NASDAQ:XBIT) Releases Quarterly Earnings Results, Misses Expectations By $0.25 EPS

Posted by Brian Himes on Aug 15th, 2026

XBiotech (NASDAQ:XBIT – Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.25), FiscalAI reports.

XBiotech Stock Performance

NASDAQ XBIT traded down $0.03 during trading on Friday, reaching $2.30. 46,499 shares of the company traded hands, compared to its average volume of 36,027. XBiotech has a 1-year low of $2.09 and a 1-year high of $3.61. The company has a market cap of $70.13 million, a price-to-earnings ratio of -1.55 and a beta of 0.84. The stock’s 50 day moving average price is $2.31 and its two-hundred day moving average price is $2.37.

Hedge Funds Weigh In On XBiotech

Several hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in XBiotech in the second quarter valued at $61,000. Bridgeway Capital Management LLC lifted its holdings in shares of XBiotech by 50.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 89,547 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 30,000 shares during the period. State Street Corp boosted its stake in shares of XBiotech by 8.5% in the 4th quarter. State Street Corp now owns 73,006 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 5,700 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of XBiotech by 25.1% in the 4th quarter. Jane Street Group LLC now owns 69,738 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 13,971 shares in the last quarter. Finally, Squarepoint Ops LLC grew its holdings in shares of XBiotech by 56.3% in the 3rd quarter. Squarepoint Ops LLC now owns 62,159 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 22,383 shares during the last quarter. Institutional investors own 55.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered shares of XBiotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Get Our Latest Research Report on XBiotech

XBiotech Company Profile

(Get Free Report)

XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.